Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown

The American telehealth company Hims & Hers Health Inc. announced on Monday that it will cease the distribution of its compounded semaglutide oral medication across the United States following a direct regulatory warning from the Food and Drug Administration (FDA). This strategic pivot comes after federal regulators prohibited the production of copycat versions of popular weight-loss drugs once the official manufacturer, Novo Nordisk, resolved its supply shortages. The FDA's move effectively ends the legal loophole that allowed compounding pharmacies to create generic versions of patented medications like Ozempic and Wegovy during periods of documented scarcity. The decision marks a significant shift for the San Francisco-based company, which had heavily marketed the compounded pills as a more affordable and accessible alternative to injectable GLP-1 treatments. Pharmaceutical compounding is typically permitted only when a drug is listed on the FDA’s official shortage database; however, as production capacities for brand-name semaglutide have stabilized, the regulatory protections for these custom-made versions have expired. Hims & Hers executives noted that while the oral compounded product will be phased out, they will continue to focus on other personalized health solutions and legal pharmaceutical offerings within their platform. Industry analysts suggest that this crackdown could disrupt the business models of several direct-to-consumer health startups that capitalized on the weight-loss drug craze. While Hims & Hers saw a significant boost in share price and revenue after launching its semaglutide line earlier this year, the company now faces the challenge of migrating those customers to alternative treatments or brand-name products. The FDA has reiterated that compounded drugs do not undergo the same rigorous pre-market review for safety and efficacy as those manufactured by patent holders, prompting stricter enforcement as supply chains return to normal. Despite the removal of the compounded oral semaglutide from its catalog, Hims & Hers maintains that its broader weight-management program remains a core pillar of its growth strategy. The company is expected to pivot toward providing access to branded GLP-1 medications and other FDA-approved weight-loss interventions. This transition highlights the volatile nature of the telehealth industry, where regulatory landscapes can shift rapidly in response to pharmaceutical supply levels and federal safety mandates.